NR3C2 and type 2 diabetes mellitus: In preclinical models of CKD in T2D, the pharmacological inhibition of the MR has been demonstrated to reduce albuminuria, kidney fibrosis, glomerular lesions, and inflammation, with beneficial cardiovascular effects.